Your shopping cart is currently empty

WEHI-P8 is an orally active inhibitor targeting the coronavirus papain-like protease (PLpro). It inhibits SARS-CoV-2 PLpro with an IC50 of 12 nM and demonstrates excellent cellular activity with an EC50 of 298 nM. Additionally, WEHI-P8 has protective effects in mice against prolonged lung and brain symptoms caused by SARS-CoV-2. This compound is applicable for research on post-COVID-19 syndrome.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | WEHI-P8 is an orally active inhibitor targeting the coronavirus papain-like protease (PLpro). It inhibits SARS-CoV-2 PLpro with an IC50 of 12 nM and demonstrates excellent cellular activity with an EC50 of 298 nM. Additionally, WEHI-P8 has protective effects in mice against prolonged lung and brain symptoms caused by SARS-CoV-2. This compound is applicable for research on post-COVID-19 syndrome. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.